ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase II clinical trial for the treatment of patients living with chronic disability following stroke, as well as that has been completed Phase I clinical trial to treat limb ischaemia. It is also involved in developing human retinal progenitor cell candidate, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, a blindness-causing disease of the retina, as well as that is in Phase I clinical trial to treat cone-rod dystrophy, an inherited eye disorder; and CTX-derived exosomes, which are nanoparticles released by cells containing various active proteins and microRNAs. ReNeuron Group plc was founded in 1997 and is headquartered in Pencoed, the United Kingdom.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+44-20-38198400
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees62
Next Earnings DateN/A
OptionableNot Optionable
ReNeuron Group (LON:RENE) Frequently Asked Questions
What is ReNeuron Group's stock symbol?
ReNeuron Group trades on the London Stock Exchange (LON) under the ticker symbol "RENE."
How were ReNeuron Group's earnings last quarter?
ReNeuron Group Plc (LON:RENE) issued its quarterly earnings results on Friday, December, 14th. The company reported ($16.80) earnings per share for the quarter. View ReNeuron Group's Earnings History.
Has ReNeuron Group been receiving favorable news coverage?
News headlines about RENE stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. ReNeuron Group earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the company's share price in the near term.
Who are some of ReNeuron Group's key competitors?
Some companies that are related to ReNeuron Group include Abattis Bioceuticals (ATTBF), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Almirall (LBTSF), AquaBounty Technologies (AQB), Arno Therapeutics (ARNI), Axim Biotechnologies (AXIM), Biocure Technology (CURE), Canada House Wellness Group (CHV), Cannabics Pharmaceuticals (CNBX), CannaRoyalty (ORHOF), Cardiome Pharma (COM), China Longyi Group Int'l (CGYG) and Creative Medical Technology (CELZ).
What other stocks do shareholders of ReNeuron Group own?
Who are ReNeuron Group's key executives?
ReNeuron Group's management team includes the folowing people:
- Mr. Olav Hellebø, CEO & Director (Age 54)
- Mr. Michael E. Hunt, CFO, Sec. & Exec. Director (Age 56)
- Dr. John David Sinden BA, MA, Ph.D., Founder & Chief Scientific Officer (Age 68)
- Dr. Randolph Corteling, Head of Research
- Mr. Shaun Stapleton BSc (Hons) MTOPRA, Head of Regulatory Affairs
How do I buy shares of ReNeuron Group?
Shares of RENE and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is ReNeuron Group's stock price today?
One share of RENE stock can currently be purchased for approximately GBX 75.50.
What is ReNeuron Group's official website?
How can I contact ReNeuron Group?
ReNeuron Group's mailing address is Pencoed Business Park, BRIDGEND, CF35 5HY, United Kingdom. The company can be reached via phone at +44-20-38198400.
MarketBeat Community Rating for ReNeuron Group (LON RENE)
MarketBeat's community ratings are surveys of what our community members think about ReNeuron Group and other stocks. Vote "Outperform" if you believe RENE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RENE will underperform the S&P 500 over the long term. You may vote once every thirty days.
